Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
October 06, 2022 08:30 ET
|
Achilles Therapeutics PLC
Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable...
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 09, 2022 07:00 ET
|
Achilles Therapeutics PLC
- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing...
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
July 21, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
June 30, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
June 21, 2022 08:30 ET
|
Achilles Therapeutics PLC
LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 10, 2022 07:00 ET
|
Achilles Therapeutics PLC
- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma - ...
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
May 09, 2022 07:00 ET
|
Achilles Therapeutics PLC
- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from...
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
May 04, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Present at Upcoming Conferences
May 03, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
April 12, 2022 07:30 ET
|
Achilles Therapeutics PLC
– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:...